Skip to main navigation Skip to search Skip to main content

Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease

  • M.E.L. Arbouw
  • , K.L.L. Movig
  • , A.C.G. Egberts
  • , P.J.E. Poels
  • , J.P.P. van Vugt
  • , J.A.M. Wessels
  • , R.J. van der Straaten
  • , C. Neef
  • , H.J. Guchelaar
  • University Medical Center Utrecht
  • extern

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)1245-1251
Number of pages7
JournalEuropean Journal of Clinical Pharmacology
Volume65
Publication statusPublished - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Econometric and Statistical Methods: General
  • Geneeskunde (GENK)
  • Farmacie/Biofarmaceutische wetenschappen (FARM)
  • Epidemiology
  • Farmacie(FARM)
  • Geneeskunde(GENK)
  • Biomedische technologie en medicijnen
  • Ziekenhuisstructuur en organisatie van de gezondheidszorg
  • Public Health
  • Pharmacology

Cite this